363 related articles for article (PubMed ID: 31690270)
1. Activation and function of receptor tyrosine kinases in human clear cell renal cell carcinomas.
Zhang Q; Liu JH; Liu JL; Qi CT; Yan L; Chen Y; Yu Q
BMC Cancer; 2019 Nov; 19(1):1044. PubMed ID: 31690270
[TBL] [Abstract][Full Text] [Related]
2. Down-regulation of CD74 inhibits growth and invasion in clear cell renal cell carcinoma through HIF-1α pathway.
Ji SQ; Su XL; Cheng WL; Zhang HJ; Zhao YQ; Han ZX
Urol Oncol; 2014 Feb; 32(2):153-61. PubMed ID: 23273913
[TBL] [Abstract][Full Text] [Related]
3. The use of protein array to identify targetable receptor tyrosine kinases for treatment of human colon cancer.
Morishita A; Gong J; Nomura T; Yoshida H; Izuishi K; Suzuki Y; Kushida Y; Haba R; D'Armiento J; Masaki T
Int J Oncol; 2010 Oct; 37(4):829-35. PubMed ID: 20811704
[TBL] [Abstract][Full Text] [Related]
4. Receptor Tyrosine Kinase Phosphorylation Pattern-Based Multidrug Combination Is an Effective Approach for Personalized Cancer Treatment.
Sun X; Song Q; He L; Yan L; Liu J; Zhang Q; Yu Q
Mol Cancer Ther; 2016 Oct; 15(10):2508-2520. PubMed ID: 27458140
[TBL] [Abstract][Full Text] [Related]
5. Clear cell renal cell carcinoma induces fibroblast-mediated production of stromal periostin.
Bakhtyar N; Wong N; Kapoor A; Cutz JC; Hill B; Ghert M; Tang D
Eur J Cancer; 2013 Nov; 49(16):3537-46. PubMed ID: 23896380
[TBL] [Abstract][Full Text] [Related]
6. Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma.
Huang D; Ding Y; Li Y; Luo WM; Zhang ZF; Snider J; Vandenbeldt K; Qian CN; Teh BT
Cancer Res; 2010 Feb; 70(3):1053-62. PubMed ID: 20103629
[TBL] [Abstract][Full Text] [Related]
7. Expression of Receptor Tyrosine Kinases on Peripheral Blood Mononuclear Cells and Tumor-Infiltrating Lymphocytes in Patients with Renal Cell Carcinoma and Healthy Donors.
Tsimafeyeu I; Volkova M; Olshanskaia A; Raskin G; Aschuba S; Khochenkova Y; Bondarenko A; Khochenkov D
Oncology; 2020; 98(4):252-258. PubMed ID: 32053815
[TBL] [Abstract][Full Text] [Related]
8. Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancer.
Nair A; Chung HC; Sun T; Tyagi S; Dobrolecki LE; Dominguez-Vidana R; Kurley SJ; Orellana M; Renwick A; Henke DM; Katsonis P; Schmitt E; Chan DW; Li H; Mao S; Petrovic I; Creighton CJ; Gutierrez C; Dubrulle J; Stossi F; Tyner JW; Lichtarge O; Lin CY; Zhang B; Scott KL; Hilsenbeck SG; Sun J; Yu X; Osborne CK; Schiff R; Christensen JG; Shields DJ; Rimawi MF; Ellis MJ; Shaw CA; Lewis MT; Westbrook TF
Nat Med; 2018 May; 24(4):505-511. PubMed ID: 29578538
[TBL] [Abstract][Full Text] [Related]
9. miR-141 is a key regulator of renal cell carcinoma proliferation and metastasis by controlling EphA2 expression.
Chen X; Wang X; Ruan A; Han W; Zhao Y; Lu X; Xiao P; Shi H; Wang R; Chen L; Chen S; Du Q; Yang H; Zhang X
Clin Cancer Res; 2014 May; 20(10):2617-30. PubMed ID: 24647573
[TBL] [Abstract][Full Text] [Related]
10. Characterization of receptor tyrosine kinase activation and biological activity of toceranib phosphate in canine urothelial carcinoma cell lines.
Korec DI; Louke DS; Breitbach JT; Geisler JA; Husbands BD; Fenger JM
BMC Vet Res; 2021 Oct; 17(1):320. PubMed ID: 34600548
[TBL] [Abstract][Full Text] [Related]
11. Tyrosine Kinase Signaling in Clear Cell and Papillary Renal Cell Carcinoma Revealed by Mass Spectrometry-Based Phosphotyrosine Proteomics.
Haake SM; Li J; Bai Y; Kinose F; Fang B; Welsh EA; Zent R; Dhillon J; Pow-Sang JM; Chen YA; Koomen JM; Rathmell WK; Fishman M; Haura EB
Clin Cancer Res; 2016 Nov; 22(22):5605-5616. PubMed ID: 27220961
[TBL] [Abstract][Full Text] [Related]
12. Metabolic and Lipidomic Reprogramming in Renal Cell Carcinoma Subtypes Reflects Regions of Tumor Origin.
Schaeffeler E; Büttner F; Reustle A; Klumpp V; Winter S; Rausch S; Fisel P; Hennenlotter J; Kruck S; Stenzl A; Wahrheit J; Sonntag D; Scharpf M; Fend F; Agaimy A; Hartmann A; Bedke J; Schwab M
Eur Urol Focus; 2019 Jul; 5(4):608-618. PubMed ID: 29452772
[TBL] [Abstract][Full Text] [Related]
13. Immunoexpression status and prognostic value of mTOR and hypoxia-induced pathway members in primary and metastatic clear cell renal cell carcinomas.
Schultz L; Chaux A; Albadine R; Hicks J; Kim JJ; De Marzo AM; Allaf ME; Carducci MA; Rodriguez R; Hammers HJ; Argani P; Reuter VE; Netto GJ
Am J Surg Pathol; 2011 Oct; 35(10):1549-56. PubMed ID: 21881486
[TBL] [Abstract][Full Text] [Related]
14. S100A10 Is a Critical Mediator of GAS6/AXL-Induced Angiogenesis in Renal Cell Carcinoma.
Xiao Y; Zhao H; Tian L; Nolley R; Diep AN; Ernst A; Fuh KC; Miao YR; von Eyben R; Leppert JT; Brooks JD; Peehl DM; Giaccia AJ; Rankin EB
Cancer Res; 2019 Nov; 79(22):5758-5768. PubMed ID: 31585940
[TBL] [Abstract][Full Text] [Related]
15. Use of protein array to investigate receptor tyrosine kinases activated in gastric cancer.
Gong J; Morishita A; Kurokohchi K; Tani J; Kato K; Miyoshi H; Inoue H; Kobayashi M; Liu S; Murota M; Muramatsu A; Izuishi K; Suzuki Y; Yoshida H; Uchida N; Deguchi K; Iwama H; Ishimaru I; Masaki T
Int J Oncol; 2010 Jan; 36(1):101-6. PubMed ID: 19956838
[TBL] [Abstract][Full Text] [Related]
16. NOTCH1 functions as an oncogene by regulating the PTEN/PI3K/AKT pathway in clear cell renal cell carcinoma.
Liu S; Ma X; Ai Q; Huang Q; Shi T; Zhu M; Wang B; Zhang X
Urol Oncol; 2013 Aug; 31(6):938-48. PubMed ID: 21993533
[TBL] [Abstract][Full Text] [Related]
17. miRNA‑205‑5p functions as a tumor suppressor by negatively regulating VEGFA and PI3K/Akt/mTOR signaling in renal carcinoma cells.
Huang J; Wang X; Wen G; Ren Y
Oncol Rep; 2019 Nov; 42(5):1677-1688. PubMed ID: 31545453
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of FABP7 promotes cell growth and predicts poor prognosis of clear cell renal cell carcinoma.
Zhou J; Deng Z; Chen Y; Gao Y; Wu D; Zhu G; Li L; Song W; Wang X; Wu K; He D
Urol Oncol; 2015 Mar; 33(3):113.e9-17. PubMed ID: 25192834
[TBL] [Abstract][Full Text] [Related]
19. Underexpression of tumour suppressor LKB1 in clear cell renal cell carcinoma is common and confers growth advantage in vitro and in vivo.
Duivenvoorden WC; Beatty LK; Lhotak S; Hill B; Mak I; Paulin G; Gallino D; Popovic S; Austin RC; Pinthus JH
Br J Cancer; 2013 Feb; 108(2):327-33. PubMed ID: 23322200
[TBL] [Abstract][Full Text] [Related]
20. Tumor-specific isoform switch of the fibroblast growth factor receptor 2 underlies the mesenchymal and malignant phenotypes of clear cell renal cell carcinomas.
Zhao Q; Caballero OL; Davis ID; Jonasch E; Tamboli P; Yung WK; Weinstein JN; ; Strausberg RL; Yao J
Clin Cancer Res; 2013 May; 19(9):2460-72. PubMed ID: 23444225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
